Proprietary precision medicine platform enabling rapid and precise drug design through iterative molecular SNAPshots using protein crystallography, cell-based assays, and in vivo models. Applied to FGFR biology and other targets for oncology and rare/genetically defined conditions.

Targets: FGFR3, FGFR4, FGFR2, FGFR1

Discontinued (1)

dabogratinib — Metastatic Urothelial Carcinoma · no further development planned due to prioritized focus on more attractive market opportunities

Biotech Distilled coverage (1)

2026-06-11 Tyra Biosciences (TYRA) — Scientific Deep Dive for Dabogratinib (TYRA-300) and the FGFR Pipeline

Articles open on Substack. Some deep dives are subscriber-only.